Preoperative Cessation of Both Dual Anti-Platelet Agents Is Safe after 1 Year in Patients Receiving Percutaneous Coronary Intervention
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The aim of this study was to investigate the atherothrombotic and bleeding risk of discontinuing both components of dual antiplatelet therapy (DAPT) before surgery in patients with an intracoronary stent after 1 year. Methods: We retrospectively enrolled 212 patients who received an evaluation of perioperative cardiac risk and underwent surgery from March 2017 to March 2019. We divided them into 2 groups: the discontinuation of both antiplatelet agents group (DCAP, no use of any antiplatelet agent) and the continuation of at least 1 antiplatelet agent group (CAP). The primary composite endpoint was the occurrence of major adverse cardiovascular events (MACE), including death, angina, postoperative coronary angiography, stroke, and readmission within 30 days postoperatively. The second endpoint was bleeding requiring the transfusion of ≥2 packs of red blood cells (RBCs) Result: A total of 136 patients were enrolled in the study, with 68 in the DCAP group and 68 in the CAP group. The occurrence of MACE did not significantly differ between the groups (25% vs. 17.6%, p=0.295). The incidence of bleeding that required a transfusion was higher in the CAP group (16.2% vs. 30.9%, p=0.044). The postoperative change in hemoglobin levels (−1.9 g/dL vs. −1.8 g/dL, p=0.742), and the number of transfused packs of RBCs (3.5 vs. 5.3, p=0.347) were not significantly different between the groups. Conclusion: Preoperative discontinuation of DAPT did not increase the risk of MACE. However, continuation of at least 1 antiplatelet agent increased the incidence of bleeding requiring RBC transfusion. Further research with a large cohort is warranted.
Abstract
Objective: The aim of this study was to investigate the atherothrombotic and bleeding risk of discontinuing both components of dual antiplatelet therapy (DAPT) before surgery in patients with an intracoronary stent after 1 year. Methods: We retrospectively enrolled 212 patients who received an evaluation of perioperative cardiac risk and underwent surgery from March 2017 to March 2019. We divided them into 2 groups: the discontinuation of both antiplatelet agents group (DCAP, no use of any antiplatelet agent) and the continuation of at least 1 antiplatelet agent group (CAP). The primary composite endpoint was the occurrence of major adverse cardiovascular events (MACE), including death, angina, postoperative coronary angiography, stroke, and readmission within 30 days postoperatively. The second endpoint was bleeding requiring the transfusion of ≥2 packs of red blood cells (RBCs) Result: A total of 136 patients were enrolled in the study, with 68 in the DCAP group and 68 in the CAP group. The occurrence of MACE did not significantly differ between the groups (25% vs. 17.6%, p=0.295). The incidence of bleeding that required a transfusion was higher in the CAP group (16.2% vs. 30.9%, p=0.044). The postoperative change in hemoglobin levels (−1.9 g/dL vs. −1.8 g/dL, p=0.742), and the number of transfused packs of RBCs (3.5 vs. 5.3, p=0.347) were not significantly different between the groups. Conclusion: Preoperative discontinuation of DAPT did not increase the risk of MACE. However, continuation of at least 1 antiplatelet agent increased the incidence of bleeding requiring RBC transfusion. Further research with a large cohort is warranted.
참고문헌 (12)
- Banerjee S, "Use of antiplatelet therapy", DAPT for post-PCI patients undergoing noncardiac surgery, 2017, pp.69, 1861~1870
- Kałuza GL, "Catastrophic outcomes of noncardiac surgery soon after coronary stenting", J Am Coll Cardiol, 35, pp.1288~1294 (2000)
- Levine GN, "2016 ACC", AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease : a report of the American College of Cardiology, J Thorac Cardiovasc Surg, pp.2016, 152[DOI]
- Burger W, "Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis", J Intern Med, 257, pp.399~414 (2005)
- Oscarsson A, "To continue or discontinue aspirin in the perioperative period : a randomized, controlled clinical trial", Br J Anaesth, 104, pp.305~312 (2010)
- Fleisher LA, "2014 ACC", AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 64[DOI]
- Hawn MT, "Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents", JAMA, 310, pp.1462~1472 (2013)
- Palmerini T, "Short-versus long-term dual antiplatelet therapy after drug-eluting stent implantation : an individual patient data pairwise and network meta-analysis", J Am Coll Cardiol, 65, pp.1092~1102 (2015)
- Devereaux PJ, "Aspirin in patients undergoing noncardiac surgery", N Engl J Med, 370, pp.1494~1503 (2014)
- Harada SACCAHA, "ACC", AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery, 2009, pp.58, 228~244
- Sarno G, "Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents : a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry(SCAAR)", Eur Heart J, 33, pp.606~613 (2012)
- Colombo A, "Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy : the SECURITY randomized clinical trial", J Am Coll Cardiol, 64, pp.2086~2097 (2014)